Ocular Therapeutix

Ocular Therapeutix gears up for pivotal trial in wet AMD
Clinical Trials Arena
Mon, 06/12/23 - 11:30 pm
Ocular Therapeutix
clinical trials
OTX-TKI
wet age-related macular degeneration
Ocular Therapeutix joins the long-acting race
EP Vantage
Wed, 09/28/22 - 10:40 am
Ocular Therapeutix
wet-AMD
wet age-related macular degeneration
OTX-TKI
Eyes itching from allergies? Ocular's Dextenza wins FDA approval as first monthly implant
Fierce Pharma
Tue, 10/12/21 - 11:47 am
Ocular Therapeutix
Dextenza
allergic conjunctivitis
FDA
Ocular Therapeutix announces topline phase 1 clinical trial results of OTX-CSI
Pharmaceutical Business Review
Mon, 10/12/20 - 10:38 am
Ocular Therapeutix
dry eye disease
clinical trials
OTX-CS1
Ocular Therapeutix announces first patient dosed in phase 1 clinical trial of OTX-CSI to treat dry eye disease
Pharmaceutical Business Review
Wed, 05/13/20 - 10:50 am
Ocular Therapeutix
dry eye disease
clinical trials
OTX-CSI
Ocular Therapeutix announces topline results of phase 3 trial of dextenza for treatment of ocular itching associated with allergic conjunctivitis
Pharmaceutical Business Review
Wed, 04/29/20 - 10:48 pm
Ocular Therapeutix
clinical trials
Dextenza
allergic conjunctivitis
Ocular's sustained-release insert misses bull's-eye in phase 3 glaucoma trial
Fierce Biotech
Tue, 05/21/19 - 09:59 am
Ocular Therapeutix
glaucoma
clinical trials
OTX-TP
Ocular Therapeutix doses first wet-AMD patient in implant trial
Drug Delivery Business News
Wed, 02/20/19 - 06:11 pm
Ocular Therapeutix
wet age-related macular degeneration
devices
OTX-TKI
Ocular Therapeutix resubmits NDA for ocular pain relief implant
Drug Delivery Business News
Fri, 06/29/18 - 09:23 pm
Ocular Therapeutix
ocular pain relief
FDA
Dextenza
devices
SEC subpoenas Ocular Therapeutix over pain relief implant
Drug Delivery Business News
Wed, 12/27/17 - 09:43 am
SEC
Ocular Therapeutix
pain relief implant
Dextenza
post-surgical pain
Ocular Therapeutix Hit by Subpoena, SEC Seeks Eye Pain Drug Documents
Xconomy
Sat, 12/23/17 - 11:55 am
Ocular Therapeutix
SEC
eye pain
Dextenza
Ocular’s new CEO to ‘aggressively’ seek partnerships
Drug Delivery Business News
Wed, 08/9/17 - 11:15 pm
Ocular Therapeutix
Antony Mattessich
Ocular Therapeutix slashes workforce following FDA rejection
Drug Delivery Business News
Wed, 08/2/17 - 09:20 am
Ocular Therapeutix
layoffs
FDA
devices
Dextenza
FDA rejects Ocular Therapeutix eye drug, citing manufacturing issues
Stat
Wed, 07/12/17 - 12:06 am
FDA
Ocular Therapeutix
Dextenza
Ocular touts patient experience data for Dextenza implant
Drug Delivery Business News
Wed, 03/15/17 - 10:15 am
devices
Ocular Therapeutix
eye health
Dextenza
post-surgical pain
Ocular Therapeutix touts data from phase III trial of Dextenza
Mass Device
Wed, 01/4/17 - 10:51 am
Ocular Therapeutix
Dextenza
devices
post-surgical ocular inflammation and pain
eye health
Biotechs line up to tap growing ophthalmics market
BioPharma Dive
Thu, 12/22/16 - 10:25 am
Ophthalmic Drugs Market
Ocular Therapeutix
Eylea
Restasis
Lucentis
Regeneron
Roche
Allergan
Regeneron picks a new delivery tech in effort to upgrade flagship blockbuster Eylea
Endpoints
Thu, 10/13/16 - 10:41 am
Regeneron
Eylea
Ocular Therapeutix
drug delivery
4 Biotech Stocks You Should Be Watching Right Now
TheStreet.com
Fri, 04/22/16 - 09:08 pm
Five Prime
Inovio
Medivation
Ocular Therapeutix
The Top 4 Biopharma Movers of the Past Week
24/7 Wall St
Sun, 02/21/16 - 11:39 am
Ocular Therapeutix
Regulus
Zafgen
Aerie Pharma

Pages